Suzette Delaloge
#153,358
Most Influential Person Now
Researcher
Suzette Delaloge's AcademicInfluence.com Rankings
Suzette Delalogecomputer-science Degrees
Computer Science
#8236
World Rank
#8658
Historical Rank
Machine Learning
#3317
World Rank
#3356
Historical Rank
Artificial Intelligence
#3619
World Rank
#3670
Historical Rank
Database
#5263
World Rank
#5463
Historical Rank
Download Badge
Computer Science
Suzette Delaloge's Degrees
- PhD Computer Science Stanford University
- Masters Artificial Intelligence University of California, Berkeley
Similar Degrees You Can Earn
Why Is Suzette Delaloge Influential?
(Suggest an Edit or Addition)Suzette Delaloge's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007) (2668)
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. (2016) (1176)
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (2017) (1086)
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy (2014) (746)
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy (2007) (525)
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2016) (393)
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (390)
- Breast cancer with synchronous metastases: trends in survival during a 14-year period. (2004) (361)
- Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial (2008) (359)
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 (2015) (333)
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array (2009) (326)
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2019) (273)
- The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. (2012) (265)
- Genomic index of sensitivity to endocrine therapy for breast cancer. (2010) (257)
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. (2014) (257)
- Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. (2009) (249)
- First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. (2012) (244)
- High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. (2012) (242)
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. (2015) (236)
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial (2020) (236)
- Dual-energy contrast-enhanced digital mammography: initial clinical results (2011) (233)
- Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. (2008) (204)
- Long-term cardiovascular mortality after radiotherapy for breast cancer. (2011) (193)
- Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. (2005) (191)
- Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. (2006) (187)
- Laser thermal therapy: Real‐time MRI‐guided and computer‐controlled procedures for metastatic brain tumors (2011) (183)
- Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. (2018) (182)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Contrast-enhanced digital mammography. (2009) (171)
- Multifactorial approach to predicting resistance to anthracyclines. (2011) (170)
- An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. (2003) (167)
- Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. (2001) (167)
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) (164)
- Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome (2010) (163)
- The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. (2004) (156)
- Risk factors for brain relapse in patients with metastatic breast cancer. (2004) (152)
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (2019) (149)
- CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study (2013) (148)
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. (2020) (147)
- REAL‐TIME MAGNETIC RESONANCE‐GUIDED LASER THERMAL THERAPY FOR FOCAL METASTATIC BRAIN TUMORS (2008) (138)
- Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. (2007) (135)
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. (2015) (135)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer (2020) (134)
- Computed-aided diagnosis (CAD) in the detection of breast cancer. (2013) (131)
- Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study (2017) (127)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. (2013) (124)
- First international consensus guidelines for breast cancer in young women (BCY1). (2014) (124)
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4) (2016) (122)
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. (2019) (118)
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (117)
- The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. (2011) (114)
- Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions. (2014) (113)
- A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers (2016) (110)
- Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? (2010) (104)
- A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients (2010) (103)
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. (2021) (101)
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. (2014) (98)
- Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. (2015) (97)
- Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. (2019) (92)
- The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer (2016) (92)
- Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. (2005) (90)
- Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. (2007) (88)
- Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort (2019) (87)
- Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study (2012) (85)
- Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer (2015) (83)
- Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. (2007) (83)
- Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. (2013) (83)
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial (2019) (82)
- Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer (2018) (82)
- A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials (2012) (81)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. (2020) (79)
- Triple-negative breast cancer: are we making headway at least? (2012) (77)
- Breast‐conserving surgery after neoadjuvant anthracycline‐based chemotherapy for large breast tumors (2004) (72)
- The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. (2013) (68)
- Biology-driven phase II trials: what is the optimal model for molecular selection? (2011) (67)
- Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. (2013) (67)
- New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. (2009) (67)
- CXCR4 expression in early breast cancer and risk of distant recurrence. (2009) (66)
- Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature (2002) (66)
- Exploring frontiers: use of complementary and alternative medicine among patients with early-stage breast cancer. (2014) (66)
- Surgical clips assist in the visualization of the lumpectomy cavity in three-dimensional conformal accelerated partial-breast irradiation. (2010) (66)
- Changes in psychological adjustment over the course of treatment for breast cancer: the predictive role of social sharing and social support (2014) (64)
- Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. (2010) (64)
- Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. (2016) (64)
- Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. (2019) (64)
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. (2019) (63)
- DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer (2010) (61)
- Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. (2007) (61)
- Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. (2009) (61)
- p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. (2008) (61)
- Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer (2006) (60)
- Ki67—no evidence for its use in node-positive breast cancer (2015) (60)
- Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications (2019) (58)
- Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study (2013) (56)
- Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO) (2019) (55)
- Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk (2020) (54)
- SARS-CoV-2 vaccines for cancer patients: a call to action (2021) (53)
- Targeted therapy-induced radiation recall. (2013) (52)
- Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. (2019) (52)
- Clinical development of mTOR inhibitors in breast cancer (2014) (52)
- Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. (2000) (51)
- Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (2020) (51)
- Chk1 as a new therapeutic target in triple-negative breast cancer. (2014) (50)
- The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ (2016) (50)
- Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. (2018) (49)
- Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes. (2013) (47)
- Outcome in breast molecular subtypes according to nodal status and surgical procedures. (2013) (46)
- Granular cell tumor of the breast (2007) (45)
- OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). (2017) (44)
- Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. (2019) (44)
- Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N‐EPIC cohort (2016) (44)
- Specimen radiography as predictor of resection margin status in non-palpable breast lesions. (2006) (43)
- A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences (2013) (43)
- Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. (2019) (42)
- Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (2016) (40)
- Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. (2014) (40)
- Targeting PI3K/AKT pathway in triple-negative breast cancer. (2017) (40)
- MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. (2020) (40)
- Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial (2018) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment (2021) (38)
- High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. (2012) (38)
- Preoperative radiotherapy in breast cancer patients: 32 years of follow-up. (2017) (37)
- Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. (2007) (37)
- Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening (2010) (36)
- Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. (2010) (36)
- Whole exome sequencing of rare aggressive breast cancer histologies (2016) (36)
- Added Value of Contrast‐Enhanced Spectral Mammography in Postscreening Assessment (2016) (36)
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). (2015) (35)
- Relation of risk of contralateral breast cancer to the interval since the first primary tumour (2009) (35)
- Therapeutic vaccines for breast cancer: Has the time finally come? (2021) (35)
- Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. (2008) (34)
- LBA9Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study (2017) (34)
- The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy (2005) (34)
- Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. (2012) (33)
- Postoperative radiotherapy in the management of adult soft tissue sarcoma of the extremities: results with two different total dose, fractionation, and overall treatment time schedules. (1999) (33)
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. (2015) (33)
- Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. (2005) (32)
- Pure and mixed mucinous carcinoma of the breast: fine needle aspiration cytology findings and review of the literature (2013) (31)
- Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial (2012) (30)
- SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (2015) (30)
- Pilot Study of the Paclitaxel, Oxaliplatin, and Cisplatin Combination in Patients With Advanced/Recurrent Ovarian Cancer (2000) (29)
- Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. (2004) (29)
- New potential and applications of contrast-enhanced ultrasound of the breast; own investigations and review of the literature (2009) (28)
- Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. (2014) (28)
- The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. (2016) (27)
- Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). (2015) (26)
- Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. (2019) (26)
- Pregnancy after breast cancer: a need for global patient care, starting before adjuvant therapy. (2010) (26)
- Gemcitabine in Patients With Solid Tumors and Renal Impairment: A Pharmacokinetic Phase I Study (2004) (25)
- The current use and attitudes towards tumor genome sequencing in breast cancer (2016) (24)
- Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort (2021) (24)
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. (2012) (24)
- Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. (2011) (23)
- Surveillance de l’endomètre des femmes sous tamoxifène (2003) (23)
- Dynamic optical breast imaging: a new technique to visualise breast vessels: comparison with breast MRI and preliminary results. (2005) (23)
- Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort (2021) (22)
- Value of whole breast magnetic resonance elastography added to MRI for lesion characterization (2018) (22)
- Steroid hormone profiling in human breast adipose tissue using semi-automated purification and highly sensitive determination of estrogens by GC-APCI-MS/MS (2017) (22)
- Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. (2017) (22)
- A Model to Predict the Risk of Upgrade to Malignancy at Surgery in Atypical Breast Lesions Discovered on Percutaneous Biopsy Specimens (2013) (22)
- Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. (2012) (21)
- Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer (2009) (21)
- Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial). (2011) (21)
- Quantification of residual risk of relapse in breast cancer patients optimally treated. (2013) (20)
- Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial. (2009) (20)
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. (2022) (20)
- Patient-assisted compression helps for image quality reduction dose and improves patient experience in mammography. (2018) (20)
- Diagnostic Performance of MR‐guided Vacuum‐Assisted Breast Biopsy: 8 Years of Experience (2016) (20)
- Outcome of full-thickness chest wall resection for isolated breast cancer recurrence. (2013) (19)
- Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study (2017) (19)
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial (2021) (19)
- Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 (2022) (19)
- Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. (2010) (19)
- Impact of COVID-19 on healthcare organisation and cancer outcomes (2021) (18)
- Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. (2008) (18)
- The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients (2020) (18)
- Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. (2017) (18)
- Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. (2013) (18)
- Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic (2021) (17)
- Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial (2012) (17)
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. (2022) (16)
- How Social Sharing and Social Support Explain Distress in Breast Cancer After Surgery: The Role of Alexithymia (2012) (16)
- Tumor characteristics and family history in relation to mammographic density and breast cancer: The French E3N cohort. (2017) (16)
- A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. (2020) (15)
- Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial (2022) (15)
- The positive non‐sentinel status is not the main decisional factor for chemotherapy assignment in breast cancer with micrometastatic disease in the sentinel lymph node (2012) (15)
- Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. (2011) (15)
- Patient satisfaction with a rapid diagnosis of suspicious breast lesions: Association with distress and anxiety (2018) (15)
- Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. (2019) (14)
- Étude pilote française de phase II d’irradiation partielle accélérée du sein conformationnelle tridimensionnelle bi-fractionnée hebdomadaire de 40 Gy (2010) (14)
- Safety of sentinel node biopsy in pregnant patients. (2005) (14)
- Factors influencing the decision to offer immediate breast reconstruction after mastectomy for ductal carcinoma in situ (DCIS): the Institut Gustave Roussy Breast Cancer Study Group experience. (2013) (14)
- Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study. (2015) (14)
- Breast pain and imaging. (2015) (13)
- T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants. (2019) (13)
- Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial (2022) (13)
- Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial (2020) (13)
- Letter to the editor: Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. (2021) (13)
- Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14) (2019) (13)
- PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients. (2018) (13)
- Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). (2016) (13)
- [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status]. (2009) (13)
- Quality of life after sentinel lymph node biopsy in early breast cancer. (2004) (13)
- Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial. (2013) (13)
- PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial (2019) (13)
- Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. (2011) (12)
- A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer (2016) (12)
- Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis (2018) (12)
- A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer (2015) (12)
- Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial (2016) (12)
- A response to “Personalised medicine and population health: breast and ovarian cancer” (2019) (12)
- Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up (2021) (12)
- First-generation genomic tests for breast cancer treatment. (2010) (12)
- Dépistage du cancer du sein : en route vers le futur (2016) (11)
- A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. (2004) (11)
- Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. (2016) (11)
- Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. (2021) (11)
- Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET) (2016) (11)
- Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations (2016) (11)
- Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial. (2020) (11)
- Effect of preoperative rescue concomitant FUN/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer. (2012) (10)
- Fine‐needle aspiration cytopathology—An accurate diagnostic modality in mammary carcinoma with osteoclast‐like giant cells (2010) (10)
- Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations (2019) (10)
- Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer (2021) (10)
- Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. (2012) (10)
- Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). (2011) (10)
- Nomogram for risk of relapse after breast-conserving surgery in ductal carcinoma in situ. (2011) (10)
- A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort (2015) (9)
- Tubular adenoma of the breast with associated mucinous features: a cytological diagnostic trap (2009) (9)
- Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis. (2015) (9)
- SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). (2012) (9)
- Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care (2022) (9)
- Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the “My Personal Breast Screening” (MyPeBS) randomised clinical trial (2022) (9)
- Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. (2022) (9)
- Impact of body mass index on overall survival in patients with metastatic breast cancer (2020) (9)
- [Breast cancer screening and diagnosis at the end of the COVID-19 confinement period, practical aspects and prioritization rules: recommendations of 6 French health professionals societies]. (2020) (9)
- Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X (2020) (8)
- Pharmacokinetic interaction involving fenofibrate and everolimus. (2015) (8)
- Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials. (2014) (8)
- Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis (2022) (8)
- Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. (2012) (8)
- [Psychological adjustment in couples facing woman's breast cancer: perceptions of spousal support]. (2014) (8)
- The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions (2012) (8)
- Decision-making from multidisciplinary team meetings to the bedside: factors influencing the recruitment of breast cancer patients into clinical trials. (2014) (8)
- AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer (2022) (8)
- What can breast cancer molecular sub-classification add to conventional diagnostic tools? (2007) (8)
- A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. (2020) (8)
- Ajustement psychologique des couples confrontés à un cancer du sein : perceptions des comportements de soutien du conjoint (2014) (8)
- A nomogram to predict for malignant diagnosis of BI‐RADS category 4 breast lesions (2010) (8)
- Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. (2022) (8)
- Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD (2018) (8)
- Abstract PD2-06: CirculatingESR1mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO) (2019) (7)
- Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer. (2016) (7)
- Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. (2022) (7)
- UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. (2019) (7)
- p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes (2008) (7)
- Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial (2019) (7)
- Letter to the Editor and reply (2003) (7)
- Utilisation de référentiels et hétérogénéité décisionnelle des indications de chimiothérapie adjuvante dans les cancers du sein exprimant les récepteurs hormonaux, HER2-négatifs: résultats d’un sondage national en France (2014) (7)
- Preclinical ex vivo evaluation of the diagnostic performance of a new device for in situ label-free fluorescence spectral analysis of breast masses (2018) (7)
- Using methylation signatures on cell-free DNA for early cancer detection: A new era in liquid biopsy? (2020) (7)
- Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. (2020) (7)
- 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial (2020) (7)
- BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes? (2008) (7)
- A new automated method to evaluate 2D mammographic breast density according to BI-RADS® Atlas Fifth Edition recommendations (2019) (7)
- Prophylactic surgery in patients with inherited risk of ovarian cancer. (2001) (7)
- Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. (2009) (7)
- 444 The EORTC 10041/BIG 03–04 MINDACT trial is feasible: first results of the pilot phase (2010) (6)
- 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial (2020) (6)
- Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (6)
- A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). (2011) (6)
- Concordance between HER‐2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients (2016) (6)
- Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort. (2018) (6)
- 290POlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC) (2017) (6)
- Tendances et évolutions de la recherche française sur le cancer du sein : étude bibliométrique (2015) (6)
- Long-term mortality in a cohort study of 6 800 French breast cancer patients treated between 1954 and 1983 (2008) (6)
- Neoadjuvant chemotherapy for breast cancers: current recommendations and future directions. (2009) (6)
- 149ONeratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial (2017) (6)
- The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification? (2014) (6)
- FGFR1 and FGF Coamplification in Breast Cancer. (2009) (5)
- Adipose Tissue Properties in Tumor-Bearing Breasts (2020) (5)
- Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort (2020) (5)
- Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. (2012) (5)
- 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial (2021) (5)
- 23 Pregnancy-associated breast cancer is as chemosensitive as classic breast cancer in the neoadjuvant setting (2010) (5)
- Individualized Prediction of Menses Recovery After Chemotherapy for Early‐stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials (2019) (5)
- Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays (2008) (5)
- Out-of-hospital follow-up after low risk breast cancer within a care network: 14-year results. (2014) (5)
- Angiomammographie : principes et applications (2008) (5)
- Abstract S6-03: The prognosis of small HER2+ breast cancers: A meta-analysis of the randomized trastuzumab trials (2013) (5)
- Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial (2019) (5)
- Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. (2019) (5)
- Tamoxifen-related uterine malignancies: carcinomas or sarcomas? (2003) (5)
- [Breast cancer screening: On our way to the future]. (2016) (5)
- Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy? (2014) (5)
- 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC) (2022) (4)
- Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. (2016) (4)
- Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study (2021) (4)
- Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study (2021) (4)
- New oral targeted therapies for metastatic breast cancer disrupt the traditional patients’ management—A healthcare providers’ view (2017) (4)
- The EUSOMA recommendations for the management of young women with breast cancer (2012) (4)
- [Subcutaneous administration of trastuzumab at home: Feedback of patients treated in 2016 by Santé service]. (2018) (4)
- Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. (2017) (4)
- Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response. (2010) (4)
- Abstract OT3-4-05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial (2012) (4)
- Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? (2017) (4)
- Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study. (2016) (4)
- Combining Genomic Profiling (70 Gene-Mammaprint) with Nodal Status Allows To Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies. (2009) (4)
- BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer (2022) (4)
- 243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. (2017) (4)
- Extended anti-HER2 therapy in early breast cancer: longer beats shorter? (2016) (4)
- Survival benefits of PARP inhibitors in advanced breast cancer: a mirage? (2020) (4)
- Primary spindle rhabdomyosarcoma of the breast in an adult female (2011) (4)
- A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016". (2020) (4)
- Evolution of overall survival according to year of diagnosis (2008-2014) and subtypes, among 16703 metastatic breast cancer (MBC) patients included in the real-life "ESME" cohort. (2017) (4)
- A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). (2010) (4)
- Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. (2017) (4)
- Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial. (2020) (4)
- Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications. (2004) (4)
- Abstract S6-6: High Independent Prognostic and Predictive Value of Circulating Tumor Cells in a Large Prospective Multicenter Trial Including Serum Tumor Markers in First Line Chemotherapy Metastatic Breast Patients (2010) (4)
- Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients (2013) (4)
- Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer. (2010) (4)
- Adenosis tumor of the breast: Cytological and radiological features of a case confirmed by histology (2008) (4)
- 279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016 (2020) (4)
- Abstract CT038: OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germlineBRCAmutation (gBRCAm) (2018) (4)
- The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual (2011) (4)
- A major genetic accelerator of cancer diagnosis: rs867228 in FPR1 (2021) (4)
- Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2020) (4)
- Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database (2021) (4)
- [Endometrial surveillance of women on tamoxifen]. (2003) (4)
- Dépistage et diagnostic du cancer du sein à la fin de période de confinement COVID-19, aspects pratiques et hiérarchisation des priorités☆ (2020) (4)
- Cancer du sein associé à la grossesse (2011) (4)
- S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse. (2011) (4)
- Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors (2007) (4)
- Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. (2012) (4)
- [Trends and evolutions of French breast cancer research: a bibliometric study]. (2015) (3)
- Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing (2020) (3)
- 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting (2021) (3)
- P5-01-07: Identification of SORBS2 as a Candidate Marker To Predict Metastatic Relapse in Breast Cancer. (2011) (3)
- Lésions bénignes du sein et risque de transformation maligne : le point de vue de l’oncologue aujourd’hui (2007) (3)
- Landscape and evolution of therapeutic research for breast cancer patients (2013) (3)
- Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (2021) (3)
- Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS (2022) (3)
- A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression. (2012) (3)
- [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. (2019) (3)
- Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions (2020) (3)
- Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system (2022) (3)
- Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4 (2013) (3)
- Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers (2021) (3)
- Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: A tissue microarray. (2009) (3)
- 177PEffects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial (2017) (3)
- Abstract P5-21-12: Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD (2018) (3)
- [Accelerated partial breast irradiation: bifractionated 40Gy in one week. A French pilot phase II study]. (2010) (3)
- Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens (2021) (3)
- Treatment of small node-negative HER2+ invasive breast carcinomas: Forty-month update of the joint Aerio/Remagus study. (2011) (3)
- MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40-70: focus on recruitment strategy in France (2022) (3)
- Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer (2017) (3)
- High prevalence of anaemia among French hospitalised cancer patients: a one-day cross-sectional survey: P1-258 (2007) (3)
- Abstract P4-13-04: Robotic nipple-sparing mastectomy with immediate prosthetic breast reconstruction : A preliminary study (2018) (3)
- Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial (2018) (3)
- Abstract OT2-10-02: Mypebs: An international randomized study comparing personalized, risk-stratified to standard breast cancer screening in women aged 40-70 (2022) (3)
- [Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey]. (2014) (3)
- [Are there any arguments against hormone replacement therapy after treatment of ovarian adenocarcinoma?]. (1997) (3)
- Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: Analysis of risk factors including the 70-gene signature (2018) (3)
- The TLR4 polymorphism predicts the response of breast cancer patients to anthracyclins (2007) (3)
- Comparative analysis of docetaxel: physical and chemical characterisation of Taxotère® and generics. (2020) (3)
- Multicentric / multifocal breast cancer with a single histotype : is the biological characterization of all individual foci justi fi ed ? (3)
- Intérêts et limites de la recherche du déficit en dihydropyrimidine déshydrogénase dans le suivi des patients traités par fluoropyrimidines : résultats de deux enquêtes nationales de pratiques réalisées auprès des médecins et des biologistes (2019) (2)
- Impact on autonomy of biweekly docetaxel as first-line chemotherapy (CT) regimen in elderly patients with metastatic breast cancer (MBC) – A FNCLCC Gerico Group Phase II multicentre trial (2008) (2)
- Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016. (2020) (2)
- A Multicenter Randomized Phase II Study of Sequential Epirubicin/Cyclophosphamide Followed by Docetaxel with or without Celecoxib or Trastuzumab According to HER2 Status, as Primary Chemotherapy for Localized Invasive Breast Cancer Patient. (2009) (2)
- 1025 Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening (2009) (2)
- Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates. (2018) (2)
- Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis. (2017) (2)
- Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy (2022) (2)
- Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III randomized adjuvant breast cancer (BC) trials. (2014) (2)
- Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (+) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results. (2013) (2)
- Predicting the efficacy of anthracyclines in breast cancer (BC): The results of the TOP trial and their validation in the BIG 00-01 trial. (2009) (2)
- Bilateral breast lesions in a patient with medullary thyroid carcinoma (2009) (2)
- Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine. (2014) (2)
- 358PDVINFLUNINE (VFL) PLUS CAPECITABINE (CAPE) FOR ADVANCED BREAST CANCER (ABC) PREVIOUSLY TREATED WITH OR RESISTANT TO ANTHRACYCLINE AND RESISTANT TO TAXANE : A PHASE 3 STUDY VERSUS CAPECITABINE. (2014) (2)
- Cxcr4 expression and risk of bone metastasis in patients with early breast cancer (2007) (2)
- Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs). (2018) (2)
- 801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents (2011) (2)
- Abstract PD13-09: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial (2021) (2)
- Laparoendoscopic Single-site Surgery (LESS) for Prophylactic Salpingo-oophorectomy Improves Cosmetic Satisfaction Compared to Standard Laparoscopy. (2015) (2)
- Abstract GS4-11: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status (2021) (2)
- Routinely collected data may usefully supplement randomised controlled data on treatment effects for mortality (2016) (2)
- 280PFICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis (2017) (2)
- Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk (2021) (2)
- Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013) (2013) (2)
- Bases génétiques de la radiosensibilité des cancers du sein (2005) (2)
- Dépistage du cancer du sein: quand l’arrière garde se met en avant…: Réponse à l’Article Publié dans « la Revue Prescrire » en Mai 2006 (Tome 26, N̊ 272 : 348) (2006) (2)
- Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study (2020) (2)
- Abstract OT3-2-06: NEOPAL: A randomized phase II study comparing RCB response to neoadjuvant chemotherapy or letrozole-palbociclib in PAM50 defined postmenopausal luminal breast cancer (2015) (2)
- BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial (2021) (2)
- Abstract P6-04-13: The role of precision medicine in "real-life" management of breast cancer patients: A survey assessing the current use and attitudes towards tumor molecular sequencing in clinical practice (2016) (2)
- Les signatures moléculaires commerciales : quelle utilité clinique ? (2015) (2)
- Comment informer une patiente qui désire une grossesse après cancer du sein (2007) (2)
- Irradiation partielle accélérée du sein tridimensionnelle conformationnelle de 40Gy bifractionnée hebdomadaire : résultats d’une étude pilote française de phase II (2010) (2)
- A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations. (2021) (2)
- Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer (2022) (2)
- Prophylactic surgery: oophorectomy or adnexectomy? (2000) (2)
- Use of progesterone receptor (PR) expression to predict benefit from prolonged adjuvant tamoxifen (TAM) in breast cancer: Results of a biomarker study from the TAM01 randomized Trial. (2016) (2)
- Mastectomie avec reconstruction mammaire immédiate : indications et techniques, algorithme de décision d’une reconstruction immédiate (2018) (2)
- My PeBS (My Personal Breast Screening) : une grande étude randomisée européenne pilotée par la France, qui évalue l’intérêt potentiel d’un dépistage du cancer du sein stratifié sur le risque (2019) (2)
- Administration de trastuzumab par voie sous-cutanée à domicile : retour d’expérience des patientes traitées en 2016 par l’hospitalisation à domicile Santé Service (2018) (2)
- Abstract P5-13-02: Decision making from multidisciplinary team meetings to bedside: factors predicting for physicians' and breast cancer patients' acceptance of clinical trials proposed by MTMs (2012) (2)
- Abstract 3208: Impact of targeted therapy on circulating tumor cells in metastatic breast cancer treated by first-line chemotherapy: IC 2006-04 study (2011) (2)
- Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial (2005) (2)
- Abstract P2-05-10: UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk (2017) (2)
- 161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC) (2022) (2)
- Predictive value of intratumoral signaling and immune infiltrate for response to preoperative (PO) trastuzumab (T) vs trastuzumab + everolimus (T+E) in patients (pts) with primary breast cancer (PBC): UNICANCER RADHER trial results. (2016) (2)
- Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer (2019) (2)
- Pharmacokinetic interaction involving fenofibrate and everolimus. (2015) (2)
- A Prospective Randomized Trial Evaluating Gene Expression Arrays to Select Neoadjuvant Chemotherapy Regimen for Operable Breast Cancer: First Report of the Remagus04 Trial (2012) (2)
- Effect of PALB2 status on breast cancer precision medicine. (2015) (2)
- Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis. (2020) (2)
- Brèves de l’AERIO (2016) (1)
- Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program. (2021) (1)
- Abstract A166: BELLE-4: A Phase II study of buparlisib and paclitaxel in women with HER2- advanced breast cancer, with or without PI3K pathway activation (2015) (1)
- Robotic nipple-sparing mastectomy with immediate prosthetic breast reconstruction: A prospective study (2018) (1)
- Abstract 2368: Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non metastatic breast cancer (2012) (1)
- Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial (2019) (1)
- 56O_PRPREDICTIVE VALUE OF AKT/MTOR PATHWAY IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS FOR RESPONSE TO PREOPERATIVE TRASTUZUMAB (T) VS TRASTUZUMAB + EVEROLIMUS (T + E) IN PATIENTS (PTS) WITH EARLY BREAST CANCER (BC): UNICANCER RADHER TRIAL RESULTS (2013) (1)
- Prognostic role of serum Ca 15-3 and circumstances of diagnostic in advanced breast cancer: Data from a prospective randomized trial. (2004) (1)
- Surgical Management for Prophylactic Oophorectomy in Women with an Inherited Risk of Ovarian Cancer (2001) (1)
- Erratum à l'article : « Dépistage du cancer du sein : en route vers le futur ¼ [Bull. Cancer 103 (2016) 753763]. (2016) (1)
- Predictive value of MRP2, p53, bcl2 and topoisomerase II immunostainings for the efficacy of anthracyclines-based adjuvant chemotherapy in breast cancer: Results from two randomized trials (2008) (1)
- Influence of loco-regional radiation therapy on subsequent cancer risk among BC pts with p53 germline mutations. (2009) (1)
- Abstract P4-09-05: Microarray anlyses of breast cancers identify CH25H, a cholesterol gene, as a potential marker and target for late metastatic reccurences. (2012) (1)
- Pattern of relapse in low‐risk breast cancer patients followed within a community care network (2017) (1)
- Clinical development of mTOR inhibitors in breast cancer (2014) (1)
- Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (2020) (1)
- The role of the genomic breast cancer index in predicting pathologic complete response in breast cancer patients treated with neoadjuvant anthracycline plus taxane. (2011) (1)
- Abstract P3-10-03: Receipt of breast cancer risk assessment and personalized prevention information among women diagnosed with a benign breast lesion (BBL) in a one stop breast unit: A prospective assessment (2016) (1)
- Rethinking breast cancer follow-up based on individual risk and recurrence management. (2022) (1)
- Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions (2022) (1)
- Is systemic disease in the coelomic epithelium associated with BRCA1 germline mutations? (2004) (1)
- Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL (2020) (1)
- Investigating the predictive value of topoisomerase II alpha (TOP2A) gene, mRNA and protein levels in anthracycline-treated estrogen receptor (ER) negative breast cancer patients. (2008) (1)
- AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. (2021) (1)
- A phase I study of the multitargeted antifolate (MTA) (LY 231514) in combination with oxaliplatin (LOHP) in metastatic solid tumors (1999) (1)
- Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project (2021) (1)
- MANAGEMENT OF BREAST CANCERS DURING PREGNANCY (2010) (1)
- Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. (2017) (1)
- O-3 Risk factors for myelodysplastic syndrome and leukemia after breast cancer: Results of a French multicenter case-control study (2005) (1)
- Breast Cancer Patients’ Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study (2021) (1)
- Douleur mammaire et imagerie (2015) (1)
- Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial (2018) (1)
- Abstract P2-09-26: Circadian Clock Genes in Primary Breast Cancer: Strong Predictors of Pathologic Response on Neoadjuvant Chemotherapy: (2010) (1)
- Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant trials. (2010) (1)
- Risk factors for brain metastases in patients with a metastatic relapse of breast cancer (2004) (1)
- Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial (2012) (1)
- Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers (2019) (1)
- Addressing the issue of bias in observational studies : Instrumental variable & Quasi-trial in ESME Research program (2018) (1)
- Abstract PS6-01: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status (2021) (1)
- Abstract P2-01-13: Prognostic value of Circulating Tumor Cells count at progressive disease after first line chemotherapy metastatic breast patients in a large prospective multicenter trial including serum tumor markers (IC 2006–04 study) (2012) (1)
- Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia). (2021) (1)
- P1-06-16: BRCA2 Mutation Carriers Respond Poorly to Conventional Anthracylins/Taxanes-Based Neo-Adjuvant Chemotherapy. (2011) (1)
- Abstract OT1-2-04: TP53 mutants in circulating tumor DNA and follow-up of BRCA1 mutation carriers: The CirCA01 study (2015) (1)
- Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial. (2021) (1)
- Prédisposition génétique aux cancers du sein et de l’ovaire: Diagnostic moléculaire et conséquences (2006) (1)
- 134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL (2020) (1)
- Abstract P2-01-04: Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study (2012) (1)
- 174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) (1)
- Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. (2015) (1)
- [How shall we inform a patient who wants a pregnancy after a breast cancer?]. (2007) (1)
- The role of radiation therapy as part of local-regional treatment in breast cancer patients with metastatic disease at diagnosis (2008) (1)
- Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies. (2020) (1)
- [Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]]. (2016) (1)
- P4-07-18: Prospective Assessment of Circulating Tumor Cells and Serum Markers for PFS Prediction in Metastatic Breast Cancer. (2011) (1)
- Breast cancer with synchronous metastases: trends in survival over a 14-year period (2004) (1)
- 1710P International multicentric evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak (2020) (1)
- Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study (2012) (1)
- Identification et prise en charge d’un haut risque de cancer du sein. État des lieux 2014 (2014) (1)
- P3-05-07: Genetic Heterogeneity of Amplification Status in Breast Invasive Carcinoma with 2+ HER2 Immunostaining: What Can We Learn? (2011) (1)
- Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort (2021) (1)
- Abstract P4-11-24: Patient's point of view on how to promote adherence to adjuvant endocrine therapy (ET): A large french survey (2022) (1)
- Prevalence of synchronous metastases of breast cancer depends both on tumor subtypes and tumor burden. (2011) (1)
- La génétique constitutionnelle peut-elle impacter la prise en charge d’une femme atteinte de cancer du sein aujourd’hui ? (2010) (1)
- Abstract OT3-3-04: ALOPREV: first cooling scalp trial for prevention of persisting alopecia after docetaxel for early breast cancer patients. (2012) (1)
- 353 Assessment of Circulating Tumor Cells and Serum Markers for Progression-free Survival Prediction in Metastatic Breast Cancer: a Prospective Observational Study (2012) (1)
- Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein (2016) (1)
- High Resolution Oligonucleotide Array-CGH and Hot Spot Mutations To Select Patients for Targeted Therapies. (2009) (1)
- Relations of circadian clocks genes with endocrine, proliferation, differentiation, and P53 mutation status in human locally invasive primary breast cancer. (2010) (1)
- Abstract PD10-08: Outcomes of germline BRCA carriers versus non-carriers in the french national metastatic breast cancer ESME cohort 2008-2016 (2021) (1)
- 43LBA Combining genomic profiling (70-gene MammaPrint) with nodal status allows to classifypatients with primary breast cancer and positive lymph nodes (1-9) into very distinct prognostic subgroups that could help tailor treatment strategies. (2009) (1)
- Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer (2022) (1)
- Irradiation conformationnelle tridimensionnelle partielle accélérée du sein : étude de faisabilité dosimétrique (2007) (1)
- Compte-rendu du Breast Cancer Symposium, San Antonio, décembre 2000 (2001) (0)
- Un oiseau rare (2015) (0)
- Existe-t-il des arguments pour contre-indiquer une hormonothérapie substitutive après traitement d'un adénocarcinome ovarien ? Données biologiques et revue de la littérature (1998) (0)
- Traitement de première ligne et survie en vie réelle des femmes âgées atteintes d'un cancer du sein métastatique RH+/HER2- par rapport aux femmes plus jeunes : résultats de l’étude observationnelle et nationale ESME (2023) (0)
- La journée diagnostique en pathologie mammaire (2004) (0)
- Mélanome malin primitif du sinus sphénoïdal: à propos d'un cas (1994) (0)
- Prédire et prévenir le cancer / Dr Suzette Delaloge et Lionel Pourteau (2017) (0)
- L’aide au diagnostic (CAD) en IRM facilite-t-elle la caracterisation des lesions malignes ? (2008) (0)
- Jusqu'où aller dans les désescalades thérapeutiques en chirurgie et radiothérapie du cancer du sein infiltrant ? (2016) (0)
- Atteinte trachéale métastatique (1994) (0)
- La thérapie thermique induite au laser. Essai clinique pilote sur une population de métastases cérébrales en échappement thérapeutique (2010) (0)
- Risques élevés de cancer du sein : quels enjeux aujourd’hui ? (2014) (0)
- 5022 A retrospective study on the efficacy of elliptinium acetate in metastatic breast cancer patients (2009) (0)
- Echographie du sein / produits de contraste (2004) (0)
- Cancer du sein: progrès en scanner et IRM (1994) (0)
- Depistage des femmes genetiquement pre-disposees (2005) (0)
- Étude rétrospective de deux modalités de radiothérapie postopératoire des sarcomes des tissus mous des extrémités (1997) (0)
- Le médecin généraliste doit favoriser l'adhésion au dépistage organisé (2012) (0)
- Place de la biopsie guidee par IRM chez les femmes a risque de cancer mammaire (2009) (0)
- Iconography : Douleur mammaire et imagerie (2015) (0)
- Enjeux des nouvelles techniques d’IRM pour l’oncologue en 2009 (2009) (0)
- Chirurgie prophylactique chez les patientes à haut risque génétique de cancer ovarien : indications et prise en charge chirurgicale pratique : Prédisposition genetique et cancers gynécologique (2004) (0)
- INTERCEPTION : construire la prévention des cancers de demain (2023) (0)
- Stratigraphic Variations of Authigenic Clay Minerals: Guadalupian Delaware Mountain Group, West Texas (1993) (0)
- Abstract P6-06-07: 5-year disease free-survival results of aggressively-treated breast cancer during pregnancy: Results from a French multicenter study (2013) (0)
- Abstract P1-14-02: Impact of loco-regional treatment (LRT) on overall-survival (OS) in patients with de novo metastatic breast cancer (MBC): Results of the French ESME multicenter national observational programme (2018) (0)
- Pilot program of fast-track germline genetic analyses as part of integrated breast, ovarian, or gastrointestinal personalized cancer care program. (2010) (0)
- Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (2023) (0)
- Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study (2018) (0)
- Abstract P3-13-02: Withdrawn (2018) (0)
- Predictive value of intratumoral signaling and immune infiltrate in primary breast cancer (PBC) for response to preoperative trastuzumab (T) vs trastuzumab + everolimus (T+E) in patients (pts) with early breast cancer (BC) : Unicancer RADHER trial results (2016) (0)
- Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (2023) (0)
- Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides (2022) (0)
- Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the HER2-positive subgroup (2019) (0)
- OT1-03-02: SAFIR01: A Molecular Screening Trial for Metastatic Breast Cancer Patients. (2011) (0)
- 38P Single molecule localization microscopy for extracellular vesicles detection in cancer (2022) (0)
- 135P Real-time genotyping-based breast cancer risk assessment in MyPeBS, an international randomized trial in the general population comparing risk-stratified to standard breast cancer screening (BCS) (2022) (0)
- Gene expression signatures can predict the efficacy of anthracyclines in HER2-negative and HER-2 positive breast cancer (BC) patients: the results of the TOP trial and their validation in the BIG 1-00 trial, on behalf of the TOP trial investigators. (2009) (0)
- Abstract P4-03-06: Initial ex-vivo study of the ability of an in situ fluorescence spectroscopy probe to distinguish benign from malignant breast tissues (2013) (0)
- 5161 Clinical and pathological aspects of 90 infra-centimetric HER2+ invasive breast cancers: a 3-centres joint AERIO/REMAGUS series (2009) (0)
- Abstract P3-06-04: Role of pMAPkinase, pAKT, p27 & IGF-IR as predictive markers of response to trastuzumab in patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy + trastuzumab in the REMAGUS02 trial (2012) (0)
- 428 The predictive value of specimen radiography to predict margins involvement in 188 breast infraclinic carcinomas (2003) (0)
- Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study (2021) (0)
- Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database (2022) (0)
- Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer (2020) (0)
- Abstract P1-14-09: Long term survival of locally advanced breast cancers (LABC) treated with neoadjuvant treatment, results of a multicenter randomised phase II study (Remagus 02 trial) (2016) (0)
- Quality of life (QOL) after long-term follow-up in patients with early breast cancer (EBC) (2008) (0)
- Is shear wave elastography (Acoustic Radiation Force Impulse) able to improve the assessment of BIRADS 4 breast solid lesions (2012) (0)
- One-stop breast unit: Acceptable levels of anxiety and good retention of information (2008) (0)
- Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer (2022) (0)
- 5021 POSTER DISCUSSION Multivariable Prognostic Model for Individual Survival Prediction of Metastatic Breast Cancer Patients Taking Into Account Circulating Tumour Cells (CTC) Count Before and During Chemotherapy (2011) (0)
- Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects? (2017) (0)
- PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial (2019) (0)
- Jean-Rémi Garbay (2017) (0)
- Abstract P3-05-14: Expression of the tumor associated carbohydrate antigen Tn and immune effectors in invasive breast cancer (2018) (0)
- Impact of chemotherapy on the nutritional status and quality of life during treatment for breast cancer (2008) (0)
- Reply to V.P. Retèl et al, D. Gauchan et al, and C. Rahilly-Tierney et al. (2015) (0)
- Abstract OT-13-05: Dolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCBG308) (2021) (0)
- Abstract PD4-10: FGFR1 / ZNF217 copy numbers and outcome in patients with node positive, HR+/Her2- early breast cancer: A genomic analysis of PACS04 trial (2018) (0)
- Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial (2011) (0)
- [Not Available]. (2016) (0)
- Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial (2022) (0)
- Abstract PD17-02: ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer (2023) (0)
- P104 Adjuvant chemotherapy plus alternated hormonal therapy (AVCF-TM) for HR+ N+ breast cancer: 13-year results of a randomized phase III trial (1998) (0)
- P2-13-06: Feasibility of Fast-Track Germline Genetic Analyses for Localized Breast Cancer Patients and Its Impact on Local Management. (2011) (0)
- Familial cancer and genetic syndromes (2012) (0)
- Abstract P1-19-19: Treatments and outcome in older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database (2020) (0)
- Abstract P6-11-07: Impact of chemotherapy on the health related quality of life among elderly patients with localized breast cancer: Findings from the prospective CANTO cohort (2020) (0)
- Abstract PD4-4: Whole exome sequencing of aggressive rare breast cancers histologic subtypes reveals novel pathway for breast cancer progression (2013) (0)
- Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications (2019) (0)
- Incidence and predictive factors of depression in patients with metastatic breast cancer: A prospective study (2005) (0)
- Feasibility of breast cancer risk assessment and personalized breast screening recommendations delivery in community practice: A national prospective study (2018) (0)
- Abstract P4-09-05: Focus on non-adherence: A qualitative exploration of perceptions associated to adjuvant endocrine therapy (ET) in premenopausal patients with breast cancer and their health care providers (HCP) (2022) (0)
- Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer. (2009) (0)
- Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial. (2023) (0)
- Contemporary picture of metastatic breast cancer: Characteristics and outcomes of 22,000 women from the ESME cohort 2008–2016 (2020) (0)
- Ecteinascidin (ET-743) in heavily pretreated refractory sarcomas: Preliminary evidence of activity (1999) (0)
- OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (2023) (0)
- Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial. (2014) (0)
- 141PSelf-questionnaire to assess patient’s preferences for participation in phase I clinical trials (2018) (0)
- Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e‐Survey Involving 32 Countries (2016) (0)
- Immunohistochemical profiles of normal and tumor breast from BRCA1 carriers and matched sporadic controls: Clues for chemoprevention (2004) (0)
- Abstract 2481: Complex deregulation of p73 transcripts in breast tissues: overexpression in benign breast fibroadenomas, and down-regulation in breast cancers (2014) (0)
- A mathematical model to predict for pre-malignant or malignant diagnosis among patients with Birad 4 breast lesions. (2006) (0)
- Abstract PD10-11: Efficacy of Platinum-based first-line chemotherapy among metastatic breast cancer (MBC) patients according to the germline BRCA1/2 mutational status: An analysis of the French ESME MBC database (2021) (0)
- 167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial (2022) (0)
- DNA arrays predictive markers of chemosensitivity to epirubicin-cyclophosphamide (EC) then docetaxel (ECD) primary chemotherapy for localized breast cancer (2008) (0)
- Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the “My Personal Breast Screening” (MyPeBS) randomised clinical trial (2022) (0)
- BRCA2: a 25-year journey from gene identification to targeted cancer treatment. (2021) (0)
- [Imaging strategy for breast cancer screening]. (2020) (0)
- 1555 BEAUTY, a large randomised controlled trial of beauty care for early stage breast cancer patients receiving adjuvant chemotherapy: Impact on body image-related quality of life (2015) (0)
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
- Determinants of therapeutic delays and their impact on axillary node involvement in operable invasive breast cancer (BC) patients (pts). (2009) (0)
- Abstract P2-06-05: Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations (2017) (0)
- Ecteinascidin-74 3: A M arine-Derived C ompound i n Advanced, P retreated S arcoma P atients—Prelimi nary Evidence o f A ctivity (2001) (0)
- Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study (2019) (0)
- High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer (2008) (0)
- Letter to the Editor (2003) (0)
- Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens (2021) (0)
- Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial (2017) (0)
- P5-13-08: Breast Cancer Index Predicts Likelihood of Breast Conservation Surgery after Neoadjuvant Chemotherapy. (2011) (0)
- Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database (2022) (0)
- Gene expression signatures can predict the efficacy of anthracyclines in HER2-negative and HER2-positive breast cancer (BC) patients: The results of the TOP trial and their validation in the BIG1-00 trial. (2009) (0)
- Do Transcriptomic Markers Provide Significant and Stable Information in Addition to Standard Markers, for the Prediction of Pathological Complete Response in Breast Cancer? (2009) (0)
- Cost-Effectiveness of a Genetic Test for Breast Cancer Risk—Letter (2014) (0)
- Evolution and landscape of clinical trials for breast cancer patients. (2012) (0)
- 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study (2021) (0)
- OT2-04-03: Uptake of a Randomized Breast Cancer Prevention Trial Comparing Letrozole to Placebo in BRCA1/2 Mutations Carriers: The FNCLCC ONCO-03/LIBER Trial. (2011) (0)
- Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials (2019) (0)
- Abstract P6-01-05: Long-Term Diagnostic Accuracy of Fine-Needle Aspiration Cytology Performed in a One Stop Clinic for the Diagnosis of Suspect Nodular Breast Lesions (2010) (0)
- PROACT: Implementing a PROACTive care pathway to empower and support breast cancer (BC) survivors. (2022) (0)
- 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT (2020) (0)
- Prospective multicentric trial evaluating prognostic and predictive value of circulating tumor cells in first-line chemotherapy metastatic breast patients. (2010) (0)
- Abstract P4-12-01: A nomogram based on clinical, imaging and histological data to predict the risk of upgrades to malignancy at surgery in biopsy-diagnosed premalignant lesions of the breast (2012) (0)
- Abstract P1-14-18: Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without celecoxib for HER2 negative tumor (Remagus 02 trial) (2012) (0)
- Title : 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (0)
- A new genomic approach to describe the natural history of node negative breast cancer patients. (2006) (0)
- Abstract P5-11-06: BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomised controlled trial (2017) (0)
- Abstract P3-01-01: Cyfra 21-1 Is Correlated with Circulating Tumor Cells Detection and Patient Outcome in Metastatic Breast Cancer: Results of a Substudy of the Prospective IC 2004-06 Trial (2010) (0)
- Abstract P5-11-22: Clinical and biological efficacy of first line AI and palbociclib in ER+ HER2- MBC with detectable circulatingESR1mutation prior to treatment initiation (2020) (0)
- Facing points of view: Representations on adjuvant endocrine therapy of premenopausal patients after breast cancer and their healthcare providers in France. The FOR-AD study. (2022) (0)
- Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. (2023) (0)
- Abstract P1-07-02: Acceptability of Breast Cancer Medical Prevention by Letrozole in Post-Menopausal Women with a BRCA1/2 Mutation in the LIBER Trial (2010) (0)
- Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial (2018) (0)
- Dynamic Breast Magnetic Resonance Imaging in the Assessment of Breast Glandular Tissue in High Risk Patients after Prophylactic Ovariectomy. (2009) (0)
- CirculatingTumor Cell Detection Predicts Early Metastatic RelapseAfter Neoadjuvant Chemotherapy in Large Operable and LocallyAdvanced Breast Cancer in a Phase II RandomizedTrial (2008) (0)
- Disease-free survival does not differ according to fertility preservation technique for young women with breast cancer. (2022) (0)
- 845 10 years experience of adjuvant radiation therapy for localised adult soft tissue sarcomas (1995) (0)
- [The sentinel lymph node in cancer of the breast: clinical aspects]. (2003) (0)
- Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD) (2017) (0)
- Abstract P4-15-02: TILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial (2019) (0)
- Use of gene expression profiling to identify fibronectin 1 and MIG as candidate biomarkers for breast cancer screening. (2009) (0)
- Validation of NAD(P)H quinone oxidoreductase (NQO1) expression as a predictive factor for adjuvant chemotherapy benefit in patients with early breast cancer. (2012) (0)
- Outcomes of 9800 metastatic luminal HER2-negative breast cancer patients in the French national real-life UNICANCER ESME-breast cohort (2018) (0)
- [Co-administration of pertuzumab and trastuzumab is practical in home hospitalization]. (2023) (0)
- Anthracyclin-related leukaemias after breast cancer (BC) adjuvant/neoadjuvant treatment: Dose relationship? (1999) (0)
- 25-gauge fibered-needle for label-free fluorescence analysis of breast masses: a first in vivo study (2018) (0)
- Abstract P1-18-09: Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcomes in 4145 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program (2022) (0)
- Iconography : Breast pain and imaging (2015) (0)
- [Breast cancer screening: when the rear-guard places itself in the vanguard...]. (2006) (0)
- hTert, MMP1, Her2 expressions by preneoplastic lesions and breast cancer risk. (2006) (0)
- P5-18-13: Adjuvant Chemotherapy with Vinorelbine+5FU or Capecitabine in Poor Responders to Neoadjuvant EC- Docetaxel Chemotherapy (NAC) for Locally Advanced Breast Cancers. (2011) (0)
- Abstract PS12-03: Letrozole and palbociclib versus 3rdgeneration chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study (2021) (0)
- EFFECTS OF LOCAL LASER TREATMENT ON VULVOVAGINAL ATROPHY FOR WOMEN WITH BREAST CANCER: A PROSPECTIVE STUDY WITH LONG-TERM FOLLOW-UP (2020) (0)
- Predictive and prognostic nomograms for breast cancer treated with primary chemotherapy (PC) (2005) (0)
- SA 4.1 Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk (2023) (0)
- Abstract P1-14-03: Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without neoadjuvant Trastuzumab for HER2 positive tumor (Remagus 02 trial) (2012) (0)
- 467P Dose escalation of TAS-117 in patients with advanced solid tumors (2022) (0)
- P4-07-04: Nomogram Including Circulating Tumor Cells (CTC) Count before and during Chemotherapy for Individual Survival Prediction of Metastatic Breast Cancer Patients. (2011) (0)
- All simulation models of breast cancer are wrong but some are useful. (2018) (0)
- Abstract 4286: Gene expression profiles in adipose tissue of cancer-bearing breasts differ from that of tumor-free breasts (2016) (0)
- 119P Evolution and Landscape of Clinical Trials for Breast Cancer Patients (2012) (0)
- Professional Attitudes Towards Treatment of Rare Histological Subtypes of Carcinomas of the Breast: An International Practice Survey (Paris Study) (2012) (0)
- Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials (2018) (0)
- Abstract P4-10-13: Therapeutic Delays, Mode of Diagnosis and Surgical Treatment of Operable Invasive Breast Cancer (BC) in Elderly Versus Non Elderly Patients in the Community (2010) (0)
- [Genetic bases of the radiosensitivity of breast cancer]. (2005) (0)
- Breast Cancer Classification to Select Patients for Cancer Treatment (2010) (0)
- Abstract OT-09-09: AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (her2−), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies (2021) (0)
- [Mastectomy and immediate reconstruction: Indications, techniques and decision algorithm]. (2018) (0)
- Risk factors for brain metastases in patients with a metastatic relapse of breast cancer. (2004) (0)
- Early Results of 3D-Conformal Accelerated Partial Breast Irradiation Dose Escalation Phase II Trial at Gustave Roussy Institute (2011) (0)
- Effective treatment based on monitoring bESR1 mutations - Authors' reply. (2023) (0)
- Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period. (2014) (0)
- CirculatingTumor Cell Detection Predicts Early Metastatic (2008) (0)
- O-195 Disease-free survival is not impacted by fertility preservation techniques for breast cancer women (2022) (0)
- Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations (2022) (0)
- A second-generation antibody–drug conjugate to treat HER2-positive breast cancer (2022) (0)
- 326 Effects of local laser treatment on vulvovaginal atrophy for women with breast cancer: a prospective study with long-term follow-up (2020) (0)
- MicroRNA expression to classify breast cancer and predict relapse. (2010) (0)
- IN13 Debate: All young early breast cancer patients should receive adjuvant chemotherapy. Against (2012) (0)
- Abstract OT1-4-05: Phase I dose-escalation study of oral administration of abexinostat (S 78454, PCI-24781) given with tamoxifen 20 mg in the treatment of patients with advanced breast cancer (2013) (0)
- Assessing the risk of severe post-treatment (tx) cancer-related fatigue (CRF) among breast cancer survivors (BCS) in the CANcer TOxicity (CANTO) cohort. (2021) (0)
- 225P Impact of potential drug-drug interactions (PDDI) on adherence to endocrine therapy (ET) among patients with breast cancer (BC) in the Health Improvement Network (THIN) (2022) (0)
- Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis. (2019) (0)
- DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib. (2022) (0)
- A response to “Personalised medicine and population health: breast and ovarian cancer” (2019) (0)
- [Molecular signatures of breast cancer: What clinical utility?]. (2015) (0)
- Abstract P1-07-02: 5-year overall survival of early breast cancer during pregnancy: A multicenter French case control study (2016) (0)
- Genetics in very young patients (2004) (0)
- Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. (2023) (0)
- Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer (2023) (0)
- PD-0432: Preoperative radiotherapy in breast cancer patients: 32-year follow-up (2015) (0)
- An exonic expression profile for breast cancer diagnosis of fine needle aspiration biopsies. (2009) (0)
- Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials. (2017) (0)
- Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort (2016) (0)
- 565 Surveillance of gene mutation carriers with mammography, ultrasound, and magnetic resonance imaging: results of a multicentric prospective trial (REMAGUS interdisciplinary group) (2010) (0)
- Sentinel node biopsy in breast cancer: clinical aspects (2003) (0)
- Overexpression of BRCA1-IRIS protein in familial ovarian cancers with no BRCA1 or BRCA2 germline mutation (2016) (0)
- Best Practice Neoadjuvant Chemotherapy for Breast Cancer : Unanswered Questions (2017) (0)
- Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials. (2023) (0)
- Abstract P5-14-01: Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial (2023) (0)
- Intensive breast cancer screening programs including MRI influence prognosis and treatment of breast cancer among BRCA 1/2 gene mutation carriers. (2009) (0)
- Change in the value of work after breast cancer: evidence from a prospective cohort (2022) (0)
- Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik. (2014) (0)
- 167MO Longitudinal evaluation of serum assessed non-adherence to tamoxifen (TAM) among premenopausal patients (pts) in the prospective multicenter CANTO cohort (2020) (0)
- [Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients]. (2021) (0)
- Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients (2016) (0)
- P1-07-10: Validation of a Diagnostic Molecular Signature (EHT Dx14) on Fine-Needle Aspirate Samples from Breast Tumors. (2011) (0)
- FNAC of a breast lesion after treatment for carcinoma (2008) (0)
- SEARCH FOR A Q-RT-PCR GENE EXPRESSION PROFILE OF BENIGN BREAST TISSUE ASSOCIATED WITH HIGH BREAST CANCER RISK (2008) (0)
- 231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers (2021) (0)
- Shared decision of adjuvant chemotherapy including a genomic test: 1 year patients reported outcomes in a multicenter, national clinical trial (UCBG-2-14) (2018) (0)
- 5023 POSTER DISCUSSION Cyfra 21-1 Correlation With Circulating Tumour Cells (CTC) Detection and Patient Outcome in Metastatic Breast Cancer: Results of a Substudy of the Prospective IC 2004-06 Trial (2011) (0)
- First clinical experience of contrast enhanced digital mammography (CEDM) for the detection of breast carcinomas. (2009) (0)
- Abstract P4-09-05: Withdrawn (2019) (0)
- Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer (2022) (0)
- Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC). (2018) (0)
- Abstract PD7-06: MAAT: Menses after adjuvant treatment. Prediction of menses recovery after chemotherapy for early breast cancer (BC) by using a nomogram model in UNICANCER PACS04 and PACS05 trials (2018) (0)
- P4-07-09: Automated Quantitative Assessment of HER2 Expression of Circulating Tumor Cells (CTC) in Metastatic Breast Cancer (IC 2006–04 Study). (2011) (0)
- Immunohistochemical profiles of normal and tumor breast from BRCA1 carriers and matched sporadic controls: Clues for chemoprevention. (2004) (0)
- [Other approaches in breast cancer screening]. (2022) (0)
- Comparison of cytopathological and histological results in 1,053 fine-needle aspiration cytology of breast lesions performed in a one-stop clinic. (2009) (0)
- 234P Germline mutations in index patients with ductal carcinoma in situ (DCIS): A single center retrospective study (2020) (0)
- 368 Anthracyclin-based neoadjuvant chemotherapy for large breast carcinoma: predictors and significance of breast preserving surgery (2003) (0)
- Abstract P2-19-01: Impact of bone-only metastatic breast cancer on outcome in a real-life setting: A comprehensive analysis of 5,041 women from the ESME database (2020) (0)
- 265PSurvival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study (2017) (0)
- Reply to 'The potential and perils of observational studies' by M. Buyse et al. (2016) (0)
- Abstract P1-07-02: Withdrawn (2018) (0)
- A Nomogram To Predict Breast Cancer Probability in Patients with Nipple Discharge. (2009) (0)
- Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy. (2011) (0)
- Factors influencing long-term altered quality of life, sexual functioning, and menopausal symptoms after prophylactic bilateral salpingo-oophorectomy (PBSO) among high-risk women (wm). (2010) (0)
- Apport de l’IRM dans le diagnostic des lesions non palpables ou occultes du sein avec envahissement ganglionnaire (2004) (0)
- Mécanismes moléculaires de résistance au cisplatine (1994) (0)
- Radiothérapie après traitement conservateur du cancer du sein : vers de nouveaux standards ? (2010) (0)
- Place du paclitaxel (Taxol®) lors de la chimiothérapie de première ligne des adénocarcinomes ovariens (1997) (0)
- Épidémiologie et prédispositions génétiques : Le cancer du sein de la femme jeune (moins de 35 ans)[1re partie: en dehors de la grossesse] (2003) (0)
- 2321 Oncologue, chirurgien, radiotherapeute, pathologiste… ce qu’ils attendent du radiologue en senologie (2004) (0)
- Cancer du sein en 2010: des avancées technologiques à une médecine encore plus personnalisée et humaine (2010) (0)
- Etude de la neoangiogenese des lesions mammaires par echographie-Doppler avec injection de produit de contraste : correlation histologique avec etude immunohistochimique (2005) (0)
- Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort (2019) (0)
- Brèves de l’AERIO (2015) (0)
- Le ganglion sentinelle dans le cancer du sein : aspects cliniques (2003) (0)
- Autres approches en dépistage du cancer du sein (2022) (0)
- L’administration conjointe de pertuzumab et trastuzumab est faisable en hospitalisation à domicile (2023) (0)
- Facteurs pronostiques de la survie sans progression chez les patientes atteintes d’un cancer du sein métastatique de type RH+/HER2- avant l’avènement des inhibiteurs CDK dans la cohorte nationale ESME (2020) (0)
- Échographie de contraste du sein (2007) (0)
- Existe-t-il des arguments pour contre-indiquer une hormonothérapie substitutive après traitement d’un adénocarcinome ovarien ? (1997) (0)
- Peut-on determiner le risque de malignite des foyers de microcalcifications mammaires suspects avant la biopsie (2006) (0)
- Définition biologique de l’agressivité tumorale : les signatures biologiques peuvent-elles être utilisées en pratique clinique ? (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Suzette Delaloge?
Suzette Delaloge is affiliated with the following schools:
